Revolution Medicines (RVMD) Non-Current Deferred Tax Liability (2019 - 2026)

Revolution Medicines' Non-Current Deferred Tax Liability history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (changed 0.0% YoY), while the FY2025 annual figure was $2.4 million, changed 0.0% from the prior year.
• Non-Current Deferred Tax Liability was $2.4 million for Q1 2026 at Revolution Medicines, roughly flat from $2.4 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $7.4 million in Q1 2022 to a low of $2.4 million in Q4 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $4.3 million across 5 years, with a median of $3.1 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability changed 0.0% in 2022, then sank 55.82% in 2023.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $7.0 million in 2022, then sank by 55.66% to $3.1 million in 2023, then retreated by 24.46% to $2.4 million in 2024, then changed by 0.0% to $2.4 million in 2025, then changed by 0.0% to $2.4 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $2.4 million (Q1 2026), $2.4 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.